Clioquinol Decreases Amyloid-β Burden and Reduces Working Memory Impairment in a Transgenic Mouse Model of Alzheimer's Disease
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Clioquinol (CQ) is a "metal protein attenuating compound" that crosses the blood-brain barrier and binds, with high affinity, copper(II) and zinc(II), two metal ions critically involved in amyloid-beta aggregation and toxicity. CQ was recently proposed for the treatment of Alzheimer's disease, but controversial data have been reported so far concerning its real therapeutic advantages. We describe here results of chronic CQ treatment in the TgCRND8 mouse model of Alzheimer's disease. Remarkably, based on classical behavioral tests, CQ treatment was found to reverse, to a large extent, the working memory impairments that are characteristic of this mouse model. Pairwise, a significant reduction of amyloid-beta plaque burden, both in the cortex and in the hippocampus, was detected as well as an attenuation of astrogliosis. MALDI Mass Spectrometry Imaging technique revealed a specific localization of CQ in the above mentioned brain areas. Modest but significant effects on the absolute and relative brain concentrations of the three most important biometals (i.e., copper, zinc, and iron) were highlighted following CQ treatment. The pharmacological and mechanistic implications of the above findings are thoroughly discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurodegenerative diseases and oxidative stress
Barnham, K. J., Masters, C. L., & Bush, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1330 · Cited by 3,683 · cited 1×
“Notably, aggregated or oligomeric Aβ can induce neurotoxicity through pathways involving free radical production and increased oxidative stress [7].”
BackgroundCopper, iron and zinc in Alzheimer's disease senile plaques
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00092-6 · Cited by 2,120
Rapid induction of Alzheimer A beta amyloid formation by zinc
Bush, A., Pettingell, W., Multhaup, G., d Paradis, M., Vonsattel, J., Gusella, J., Beyreuther, K., Masters, C., & Tanzi, R. (1994) · Science · doi:10.1126/science.8073293 · Cited by 1,522 · cited 1×
“Metal binding typically leads to protease resistance and reversible precipitation [15,19–21] as well as to production of hydrogen peroxide and asso-”
BackgroundCherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268 · cited 1×
“permeability [5]; their concentration correlates with the degree of cognitive impairment in AD patients [6].”
BackgroundAtwood, C. S., Moir, R. D., Huang, X., Scarpa, R. C., Bacarra, N. M. E., Romano, D. M., Hartshorn, M. A., Tanzi, R. E., & Bush, A. I. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.21.12817 · Cited by 1,009
Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988 · cited 2×
“Based on prior reports on AD patients [29] and on mouse models of neurodegenerative diseases [27,57] linking the beneficial therapeutic effects of CQ to the possible chelation of metals in the brain and/or to attenuation of specific metal-protein interactions, we determined whether CQ treatment might affect Cu, Fe, an…”
BackgroundChishti, M. A., Yang, D.-S., Janus, C., Phinney, A. L., Horne, P., Pearson, J., Strome, R., Zuker, N., Loukides, J., French, J., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100710200 · Cited by 955 · cited 3×
“TgCRND8 mice exhibit cerebral amyloid deposition and MWM memory impairment by 3 months of age [38].”
BackgroundInfluentialAdlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Liu, X., Smith, J. P., Perez, K., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.018 · Cited by 672
Atwood, C. S., Scarpa, R. C., Huang, X., Moir, R. D., Jones, W. D., Fairlie, D. P., Tanzi, R. E., & Bush, A. I. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751219.x · Cited by 641
Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo
Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620
Common mechanisms of amyloid oligomer pathogenesis in degenerative disease
Glabe, C. G. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.04.017 · Cited by 569 · cited 1×
“permeability [5]; their concentration correlates with the degree of cognitive impairment in AD patients [6].”
BackgroundAqueous Dissolution of Alzheimer's Disease Aβ Amyloid Deposits by Biometal Depletion
Cherny, R. A., Legg, J. T., McLean, C. A., Fairlie, D. P., Huang, X., Atwood, C. S., Beyreuther, K., Tanzi, R. E., Masters, C. L., & Bush, A. I. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23223 · Cited by 482
Copper-Dependent Inhibition of Human Cytochrome c Oxidase by a Dimeric Conformer of Amyloid-β1-42
Crouch, P. J., Blake, R., Duce, J. A., Ciccotosto, G. D., Li, Q.-X., Barnham, K. J., Curtain, C. C., Cherny, R. A., Cappai, R., Dyrks, T., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4276-04.2005 · Cited by 327
Metals and Alzheimer's disease
Adlard, P. A., & Bush, A. I. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-102-303 · Cited by 324
White, A. R., Du, T., Laughton, K. M., Volitakis, I., Sharples, R. A., Xilinas, M. E., Hoke, D. E., Holsinger, R. M. D., Evin, G., Cherny, R. A., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602487200 · Cited by 284 · cited 1×
“Promoting Aβ clearance might be achieved through a specific modulation of metal sequestration or through modification of metal-protein interactions [70].”
BackgroundAluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice
Praticò, D., Uryu, K., Sung, S., Tang, S., Trojanowski, J. Q., & Lee, V. M. ‐. (2002) · The FASEB Journal · doi:10.1096/fj.02-0012fje · Cited by 278 · cited 1×
“, copper, zinc, and iron as well as nonphysiological aluminum, both in Aβ aggregation and in increased Aβ toxicity [8–13].”
BackgroundNguyen, T., Hamby, A., & Massa, S. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502177102 · Cited by 194
Fukami, S., Watanabe, K., Iwata, N., Haraoka, J., Lu, B., Gerard, N. P., Gerard, C., Fraser, P., Westaway, D., George-Hyslop, P. S., et al. (2002) · Neuroscience Research · doi:10.1016/s0168-0102(02)00015-9 · Cited by 157 · cited 1×
“These transgenic animals have earlier been characterized at a behavioral and histopathological level by our group [36] and by several others [37–50].”
Copper and zinc dismetabolism in the mouse brain upon chronic cuprizone treatment
Zatta, P., Raso, M., Zambenedetti, P., Wittkowski, W., Messori, L., Piccioli, F., Mauri, P. L., & Beltramini, M. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5073-8 · Cited by 84 · cited 1×
“For instance, large ionophoric effects were reported by Zatta and colleagues [79] when treating mice with the copper chelator cuprizone; wide increases in the brain concentrations of copper and zinc were described in that case.”
BackgroundSelf-citationImpaired conditioned taste aversion learning in APP transgenic mice
Janus, C., Welzl, H., Hanna, A., Lovasic, L., Lane, N., St. George-Hyslop, P., & Westaway, D. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.11.007 · Cited by 51 · cited 1×
“These transgenic animals have earlier been characterized at a behavioral and histopathological level by our group [36] and by several others [37–50].”
Background
Cited by
Mass Spectrometric Imaging for Biomedical Tissue Analysis
Chughtai, K., & Heeren, R. M. A. (2010) · Chemical Reviews · doi:10.1021/cr100012c · Cited by 652
Heavy metal toxicity: An update of chelating therapeutic strategies
Kim, J.-J., Kim, Y.-S., & Kumar, V. (2019) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2019.05.003 · Cited by 635
Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics
Belaidi, A. A., & Bush, A. I. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13425 · Cited by 578
Copper in the brain and Alzheimer’s disease
Hung, Y. H., Bush, A. I., & Cherny, R. A. (2010) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-009-0600-y · Cited by 498
Biological metals and metal-targeting compounds in major neurodegenerative diseases
Barnham, K. J., & Bush, A. I. (2014) · Chem. Soc. Rev. · doi:10.1039/c4cs00138a · Cited by 497
Metadata
- Authors
- Grossi, C., Francese, S., Casini, A., Rosi, M. C., Luccarini, I., Fiorentini, A., Gabbiani, C., Messori, L., Moneti, G., & Casamenti, F.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2009-06-05
- Volume
- 17
- Issue
- 2
- Pages
- 423-440
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1961159442
- Cited by
- 129
- References
- 22
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.